hit counter
ContraFect Corporation (CFRX) Stock News Sentiment & Price - Sentifly
CFRX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



ContraFect Corporation (CFRX)

USA
Biotechnology
NASDAQ
CFRX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CFRX Latest news
GlobeNewsWire
Neutral
ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021
2021-09-29 07:30

Data Being Presented Demonstrates Directly Positive Clinical Utility and Furthers the Understanding of Exebacase in Treating Staphylococcus aureus Bacteremia, Including Multidrug-Resistant MRSA Data Being Presented Demonstrates Directly Positive Clinical Utility and Furthers the Understanding of Exebacase in Treating Staphylococcus aureus Bacteremia, Including Multidrug-Resistant MRSA

GlobeNewsWire
Neutral
ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference
2021-09-22 07:30

YONKERS, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Cantor Global Virtual Healthcare Conference, which is being held from September 27 – 30, 2021. The fireside chat will be held on Wednesday, September 29 at 11:20 AM ET.

Seeking Alpha
Positive
ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market
2021-09-15 08:00

CFRX is developing a medicine to treat bacterial infections without using an antibiotic. Phase 2 trials have shown outstanding data against MRSA infections, and reduced hospital time.

GlobeNewsWire
Neutral
ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update
2021-08-13 07:30

Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company's DLA portfolio

GlobeNewsWire
Neutral
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
2021-07-19 07:31

YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced multiple presentations, including two oral presentations, of data from its portfolio of DLAs from the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), now available online.

GlobeNewsWire
Neutral
ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity
2021-07-19 07:30

YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the publication of two manuscripts that demonstrate the potent in vivo activity of CF-296, a novel engineered lysin agent with potent bactericidal and anti-biofilm activity against Staphylococcus aureus (Staph aureus), a life-threatening pathogen.

GlobeNewsWire
Neutral
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development
2021-06-17 07:31

YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Gary Woodnutt, Ph.D. has been appointed as Senior Vice President of Translational Sciences and Preclinical Development. Dr. Woodnutt will oversee the scientific strategy for the Company's early stage assets and the performance of the extensive translational programs required to proceed into clinical trials. He will have a pivotal role in the regulatory strategy for the preclinical aspects of Investigational New Drug (IND) applications as well as the potential BLA for exebacase. Dr. Woodnutt has over 30 years of experience leading the discovery and development of innovative therapies ranging from antibiotics to novel protein-based therapeutics.

GlobeNewsWire
Neutral
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum
2021-06-17 07:30

YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced multiple presentations, including two oral presentations, of data from its portfolio of DLAs at the 2021 World Microbe Forum, being held virtually from June 20-24, 2021.

GlobeNewsWire
Neutral
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections
2021-05-26 07:30

Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function

GlobeNewsWire
Neutral
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
2021-05-14 07:30

Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021

Loading more news...